Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 53

HOS-112188 · Präparat HOS-093615

Potential P-gp inhibition by REYATAZ is unknown and cannot be excluded. Edoxaban Potential for increased edoxaban Exercise caution when concentrations which can result in a higher edoxaban is used with risk of bleeding. The mechanism of REYATAZ. interaction is P-gp inhibition by REYATAZ/ritonavir. Please refer to the edoxaban SmPC sections 4.2 and 4.5 for Ritonavir is a strong P-gp inhibitor. appropriate edoxaban dosage recommendations for Potential P-gp inhibition by REYATAZ is co-administration with P-gp unknown and cannot be excluded. inhibitors. Vitamin K antagonists Warfarin Co-administration with REYATAZ has the It is recommended that the potential to increase or decrease warfarin International Normalised Ratio concentrations. (INR) be monitored carefully during treatment with REYATAZ, especially when commencing therapy. ANTIEPILEPTICS Carbamazepine REYATAZ may increase plasma levels of Carbamazepine in combination carbamazepine due to CYP3A4 inhibition. with REYATAZ (with or without ritonavir) is Due to carbamazepine inducing effect, a contraindicated due to the risk reduction in REYATAZ exposure cannot for loss of virologic response be ruled out. and development of resistance (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) vitamin K (HOS-091176) edoxaban (HOS-086234) ritonavir (HOS-084521) warfarin (HOS-085950)